Trial Profile

A Phase 1/2 Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa Associated With NR2E3 and RHO Mutations and Leber Congenital Amaurosis With Mutation(s) in CEP290 Gene

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs OCU 400 (Primary)
Indications Leber congenital amaurosis; Retinitis pigmentosa
Focus Adverse reactions
Sponsors Ocugen

Most Recent Events

03 Feb 2025 Planned End Date changed from 1 Dec 2024 to 1 Mar 2027.
03 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Mar 2027.
13 Jan 2025 Results published in the Ocugen Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com